camptothecin has been researched along with Lymphoma, T-Cell in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, Y; Fujita, Y; Fukushima, Y; Iwao, H; Jin, ZX; Kawanami, T; Masaki, Y; Miki, M; Nakajima, A; Nakajima, H; Okazaki, T; Sakai, T; Sawaki, T; Tong, XP; Umehara, H; Yue, S | 1 |
| Bessho, M; Higashihara, M; Kohori, M; Niitsu, N | 1 |
| Ohnishi, K; Ohno, R | 1 |
| Kizaki, H; Oguro, M; Onishi, Y | 1 |
| Bloom, SE; Muscarella, DE; Rachlinski, MK; Sotiriadis, J | 1 |
| Kumagai, K; Sakai, C; Saotome, T; Takagi, T; Tamaru, J | 1 |
1 review(s) available for camptothecin and Lymphoma, T-Cell
| Article | Year |
|---|---|
[New antitumor drugs for malignant lymphoma: a review].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carubicin; Clinical Trials, Phase II as Topic; Female; Humans; Irinotecan; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Piperazines | 1994 |
2 trial(s) available for camptothecin and Lymphoma, T-Cell
| Article | Year |
|---|---|
Phase II study of the irinotecan (CPT-11), mitoxantrone and dexamethasone regimen in elderly patients with relapsed or refractory peripheral T-cell lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Lymphoma, T-Cell; Male; Mitoxantrone; Natriuretic Peptides; Neoplasm Recurrence, Local; Stroke Volume; Troponin T; Ventricular Function, Left | 2007 |
Combination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Doxorubicin; Drug Administration Schedule; Humans; Irinotecan; Leukopenia; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Recurrence | 2000 |
3 other study(ies) available for camptothecin and Lymphoma, T-Cell
| Article | Year |
|---|---|
Synergistic effects of topoisomerase I inhibitor, SN38, on Fas-mediated apoptosis.
Topics: Animals; Antibodies, Monoclonal; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Caspase 3; Cell Cycle Proteins; Cell Line, Tumor; Checkpoint Kinase 1; DNA-Binding Proteins; Drug Synergism; Enzyme Activation; fas Receptor; Humans; Irinotecan; Lymphoma, T-Cell; Mice; Protein Kinases; Protein Serine-Threonine Kinases; Topoisomerase I Inhibitors; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2010 |
A lymphoma cell line resistant to 4-piperidinopiperidine was less sensitive to CPT-11.
Topics: Antineoplastic Agents; Camptothecin; Cell Division; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Etoposide; Humans; Irinotecan; Lymphoma, T-Cell; Piperidines; Tumor Cells, Cultured | 1997 |
Contribution of gene-specific lesions, DNA-replication-associated damage, and subsequent transcriptional inhibition in topoisomerase inhibitor-mediated apoptosis in lymphoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Transformation, Viral; Chickens; Dactinomycin; DNA Damage; DNA Replication; DNA, Ribosomal; Etoposide; Genes, myc; Kinetics; Lymphoma, B-Cell; Lymphoma, T-Cell; Topoisomerase I Inhibitors; Transcription, Genetic; Tumor Cells, Cultured | 1998 |